These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 15534665)

  • 1. [Hypertriglyceridemia--diagnostics, risk and treatment].
    Hexeberg S; Retterstøl K
    Tidsskr Nor Laegeforen; 2004 Nov; 124(21):2746-9. PubMed ID: 15534665
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-chain omega-3 fatty acids, fibrates and niacin as therapeutic options in the treatment of hypertriglyceridemia: a review of the literature.
    Ito MK
    Atherosclerosis; 2015 Oct; 242(2):647-56. PubMed ID: 26296750
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The association between fibrate use, change in high-density lipoprotein cholesterol, and the risk of cardiovascular disease: a retrospective chart review involving up to 8 years of follow-up.
    Nichols GA; Koro CE; Chan W; Bowlin SJ; Sprecher DL
    Clin Ther; 2006 Feb; 28(2):243-50. PubMed ID: 16678645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of high-risk older persons with lipid-lowering drug therapy.
    Aronow WS
    Am J Ther; 2008; 15(2):102-7. PubMed ID: 18356628
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.
    Hausenloy DJ; Yellon DM
    Heart; 2008 Jun; 94(6):706-14. PubMed ID: 18480348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Comparison of the effects of omega-3 polyunsaturated fatty acids and Olbetam (Acipimox) in the treatment of hypertriglyceridemia].
    Zák A; Zeman M; Vítková D
    Cas Lek Cesk; 1994 Dec; 133(24):755-8. PubMed ID: 7834677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-density lipoprotein as a therapeutic target: clinical evidence and treatment strategies.
    Toth PP
    Am J Cardiol; 2005 Nov; 96(9A):50K-58K; discussion 34K-35K. PubMed ID: 16291015
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beyond LDL cholesterol: the role of elevated triglycerides and low HDL cholesterol in residual CVD risk remaining after statin therapy.
    Alagona P
    Am J Manag Care; 2009 Mar; 15(3 Suppl):S65-73. PubMed ID: 19355805
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prescription omega-3 fatty acids and their lipid effects: physiologic mechanisms of action and clinical implications.
    Bays HE; Tighe AP; Sadovsky R; Davidson MH
    Expert Rev Cardiovasc Ther; 2008 Mar; 6(3):391-409. PubMed ID: 18327998
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The benefit of fibrates in the treatment of 'bad HDL-C responders to statins'.
    Devroey D; Velkeniers B; Duquet W; Betz W
    Int J Cardiol; 2005 May; 101(2):231-5. PubMed ID: 15882669
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized study of the safety and efficacy of fish oil (omega-3 fatty acid) supplementation with dietary and exercise counseling for the treatment of antiretroviral therapy-associated hypertriglyceridemia.
    Wohl DA; Tien HC; Busby M; Cunningham C; Macintosh B; Napravnik S; Danan E; Donovan K; Hossenipour M; Simpson RJ
    Clin Infect Dis; 2005 Nov; 41(10):1498-504. PubMed ID: 16231263
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Statins and omega-3 fatty acids in the treatment of dyslipidemia and coronary heart disease.
    Nordøy A
    Minerva Med; 2002 Oct; 93(5):357-63. PubMed ID: 12410168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. What is the most effective strategy for managing diabetic dyslipidaemia?
    Reasner CA
    Atheroscler Suppl; 2005 Sep; 6(3):21-7. PubMed ID: 16054442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination therapy with statins and omega-3 fatty acids.
    Nambi V; Ballantyne CM
    Am J Cardiol; 2006 Aug; 98(4A):34i-38i. PubMed ID: 16919515
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
    Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S
    Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The "second atherogenic phenotype" or the role of insulin resistance in vascular risk].
    Ziegler O; Guerci B; Drouin P
    Arch Mal Coeur Vaiss; 1998 Oct; 91 Spec No 5():33-9. PubMed ID: 9833078
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The importance of recognizing and treating low levels of high-density lipoprotein cholesterol: a new era in atherosclerosis management.
    Cardenas GA; Lavie CJ; Cardenas V; Milani RV; McCullough PA
    Rev Cardiovasc Med; 2008; 9(4):239-58. PubMed ID: 19122582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacologic treatment of type 2 diabetic dyslipidemia.
    Moon YS; Kashyap ML
    Pharmacotherapy; 2004 Dec; 24(12):1692-713. PubMed ID: 15585439
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of ezetimibe in patients who cannot tolerate statins or cannot get to the low density lipoprotein cholesterol target despite taking a statin.
    Gazi IF; Daskalopoulou SS; Nair DR; Mikhailidis DP
    Curr Med Res Opin; 2007 Sep; 23(9):2183-92. PubMed ID: 17692154
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bridging the gap in treatment options for patients with hypertriglyceridemia.
    Underberg JA; Hays R
    J Fam Pract; 2007 Dec; 56(12 Suppl New):S24-31. PubMed ID: 18664339
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.